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background: Previous research has demonstrated the cost-effectiveness of pVAD hemodynamic support for emergent and elective high-risk 
heart failure patients. In addition, our published budget impact models show a minimal per-member-per-month impact for payers. Consistent with 
health reform trends, this study’s objective is to further confirm these findings by extending the timeframes and databases analyzed with a focus 
on the longitudinal impact of pVADs on readmissions and post-index costs in the under-studied cohort of urgent patients in need of hemodynamic 
stabilization.
Methods: Multiple industry data sets across multiple years (2009 to 2012) were accessed for this study, including Optum Insights, MedPAR, 
state-mandated all-payer claims data and CMS’s Standard Analytical File (SAF). Total populations under review approached 75 million members. 
Longitudinal analyses of up to two years after post-index events were conducted to assess readmission rates and other key resource consumption 
metrics.
results: In the cardiogenic shock (CS) cohort, reductions in index LOS with pVAD support were confirmed, with a 41.3% reduction versus 
surgical hemodynamic support alternatives (32.1 vs. 54.7 days). CS pVAD readmission rates (14.1%) are trending downward relative to surgical 
hemodynamic support alternatives (15.7%) and IABP (16.2%). CS post-index costs were reduced by 29% ($53,310 for pVAD vs. $75,554 for surgical 
hemodynamic support), primarily due to less hospital care. In the high-risk PCI cohort, the index LOS reduction with pVAD support was 31.0% (8.7 
vs. 6.0 days). Moreover, post-index costs were reduced by 42% for outpatient hospital care and virtually eliminated for pharmacy services (93% 
reduction from $3,240 to $229 per case). Other subgroup analyses will also be presented.
conclusion: This multi-database study demonstrates that pVAD technology continues to favorably influence key resource consumption metrics that 
will allow providers, payers and ACOs to more effectively manage these high-risk patients both clinically and economically.
